Literature DB >> 1964720

C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor.

J L Krstenansky1, T J Owen, M H Payne, S A Shatzer, S H Buck.   

Abstract

Neuropeptide Y (NPY) is known to bind to at least two types of receptors (Y1 & Y2). One type (Y2) is able to bind and undergo activation by both NPY and its C-terminal fragments with good potency while the other (Y1) requires the full length of NPY for good potency. For most NPY analogs that have been examined, potency for the Y2 system (porcine spleen) is greater than or equal to that for the Y1 system (mouse brain), since the Y2 system is generally less selective. However, modifications of NPY and its analogs at position 34 can lead to materials with some Y1 selectivity. For example, [Pro34]-pNPY binds to mouse brain with an affinity of 0.14 nM. Its affinity for porcine spleen is 140 nM. [His34]-pNPY was also found to be Y1 selective (19-fold), but not to the degree of the [Pro34] analog (1000-fold). The Pro34 modification in the Y2 selective C-terminal fragment NPY (20-36) converted it into an essentially non-selective analog. The selectivity from the Pro34 substitution results from a loss of Y2 binding potency along with little effect on the Y1-receptor binding. Therefore, Y1 and Y2 receptors have differing requirements for the C-terminal region of NPY in addition to their different requirements for NPY's N-terminus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964720     DOI: 10.1016/0143-4179(90)90073-8

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  7 in total

1.  Neuropeptide Y directly inhibits neuronal activity in a subpopulation of gonadotropin-releasing hormone-1 neurons via Y1 receptors.

Authors:  Ulrike Klenke; Stephanie Constantin; Susan Wray
Journal:  Endocrinology       Date:  2010-03-29       Impact factor: 4.736

2.  Neuropeptide Y, peptide YY and C-terminal fragments release histamine from rat peritoneal mast cells.

Authors:  L Grundemar; R Håkanson
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

3.  Neuropeptide Y depresses GABA-mediated calcium transients in developing suprachiasmatic nucleus neurons: a novel form of calcium long-term depression.

Authors:  K Obrietan; A N van den Pol
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

4.  Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.

Authors:  R Abounader; J G Villemure; E Hamel
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

5.  Functional effects and ligand binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types.

Authors:  U Kahl; U Langel; T Bartfai; L Grundemar
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

6.  Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a non-peptide antagonist.

Authors:  F Feth; W Rascher; M C Michel
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

7.  Characterization of vascular neuropeptide Y receptors.

Authors:  L Grundemar; S E Jonas; N Mörner; E D Högestätt; C Wahlestedt; R Håkanson
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.